ClinicalTrials.gg
RecruitingNCT07285850ABATE-MASLDUpdated Dec 16, 2025

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

A Phase 2/3 interventional study of Sequential treatment of bevacizumab combined with atezolizumab (sequential group) and Simultaneous treatment of bevacizumab combined with atezolizumab (same period group) in HCC - Hepatocellular Carcinoma, sponsored by Eastern Hepatobiliary Surgery Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Eastern Hepatobiliary Surgery Hospital · Phase 2/3, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Eastern Hepatobiliary Surgery Hospital.

Planned enrollment
43rd of 44
20 · median 170
Started
2025
with 1 other
Phase 2/3
4 of 51
1 open now
Registered
47th of 51
by date

Among the 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital, this one is the 43rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 2/3, and was the 47th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

6 of the 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Carcinoma, Hepatocellular by Eastern Hepatobiliary Surgery Hospital, or all of them as a file.
02

Study summary

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Read the detailed description

The study will recruit 20 patients, randomly dividing them into sequential and concurrent groups for up to 6 months of treatment and follow-up. In addition to routine efficacy assessments, the study will analyze changes in the microenvironment before and after treatment, including T-cell calcium levels, VEGFA expression, and immune-related factor alterations. Furthermore, it will explore the relationship between T-cell calcium signaling genes and treatment response, evaluating the impact of baseline metabolic characteristics (such as blood lipids and insulin resistance) on therapeutic outcomes.

In terms of safety, the study will monitor all adverse events (AEs) and serious adverse events (SAEs), and classify them according to the CTCAE 5.0 criteria. During the treatment period, patients will undergo regular liver biopsy to assess changes in the tumor microenvironment. The ultimate goal of the study is to provide evidence-based precision treatment strategies for MASLD-HCC patients.

03

Conditions studied

  • HCC - Hepatocellular Carcinoma

Keywords

  • MASH
  • HCC
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Eligibility Criteria Inclusion Criteria

  • Age ≥ 18 years old (gender not limited)
  • performance status of 0-1
  • Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
  • Ultrasound or MRI indicating moderate to severe fatty liver (Fibroscan CAP > 268 dB/m or MR fat score > 10%)
  • Willing to use measures during the trial period
  • Expected survival time ≥ 3 months
  • At least one (per 1.1) that has not been irradiated
  • Organ function levels (within 7 days before first study medication) must meet the following:
  • Hematopoietic function: ≥ 1.5×10⁹/L, ≥ 100×10⁹/L, ≥ 90 g/L, no transfusion within 14 days
  • Liver function: ≤ 1.5×, /ALT/ALP ≤ 2.5×ULN, serum creatinine ≤ 1.5×ULN, ≥ 50 mL/min, ALB ≥ 30 g/L, A
  • Coagulation function: and APTT ≤ 1.5×ULN or within therapeutic range if on anticoagulants
  • Renal function: urinary protein ≤ 1+ (or ≤1 g/24h if >1+)
  • Cardiac function: normal or clinically insignificant, > 50%
  • Women of must have a negative serum pregnancy test within 7 days prior to first dosing
  • Men and women of must use effective contraception during and for 12 months after treatment
  • Participants must voluntarily provide and have good compliance

Exclusion Criteria

  • Excessive alcohol consumption (weekly ethanol intake: males \< 210 g, females \< 140 g)
  • Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
  • Pregnant or breastfeeding women, or positive pregnancy test at baseline
  • Central nervous system diagnosed by CT, MRI, or PET-CT
  • Participation in another clinical drug or therapy trial within 4 weeks before first study dose
  • Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
  • Radiotherapy within 2 weeks before first study dose
  • History or presence of primary immunodeficiency or active disease
  • History of organ transplantation or hematopoietic stem cell transplantation
  • Current use of or (>10 mg/day prednisone or equivalent) within 2 weeks
  • Positive for antibody or Treponema pallidum antibody, or active /C infection
  • Allergy to recombinant humanized monoclonal antibody, VEGF monoclonal antibody, or components
  • Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
  • Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
  • Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, , embolism)
  • History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
  • Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
  • Active pulmonary disease (interstitial pneumonia, , asthma, tuberculosis history)
  • Abnormal coagulation (INR > 2.0, PT > 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
  • Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
  • Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
  • History of substance abuse or mental disorders affecting compliance
  • Use of warfarin or coumarin derivatives within 14 days before or during treatment
  • Other severe acute/chronic conditions increasing risk or confounding results
  • Poor compliance or other conditions deemed unsuitable for trial participation
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

    Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

    Drug: Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

  • Active comparator
    Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

    Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

    Drug: Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Interventions

  • DrugSequential treatment of bevacizumab combined with atezolizumab (sequential group)

    The first cycle (3 weeks) receives bevacizumab monotherapy, and from the second cycle onwards, it is combined with atezolizumab until disease progression or intolerable toxicity.

  • DrugSimultaneous treatment of bevacizumab combined with atezolizumab (same period group)

    Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. objective response rate (ORR)

    Compare the objective response rate (ORR) of sequential treatment with bevacizumab combined with atezolizumab (sequential group) and concurrent treatment (concurrent group) in advanced HCC under MASLD background, according to RECIST 1.1 criteria.

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2025
First posted
Dec 16, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07285850
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Responsible party
Shen Feng (Director of Clinical Research Institute, Eastern Hepatobiliary Surgery Hospital) — Principal investigator
First posted
Dec 16, 2025
Start date
Oct 20, 2025
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Dec 16, 2025

Study contacts

Hao Shen, M.D.
Contact
shenhaochina@163.com
18952681068

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion